[{"question_number":"6","question":"Susac syndrome is associated with a clinical triad of which of the following?","options":["Visual loss caused by branch retinal artery occlusions","Sensorineural hearing loss","Subacute encephalopathy","All of the above"],"correct_answer":"D","correct_answer_text":"All of the above","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Visual loss caused by branch retinal artery occlusions is a hallmark of Susac syndrome but alone does not constitute the full clinical picture. Ophthalmic involvement typically manifests as sudden, painless visual field deficits or scotomas on automated perimetry. Fluorescein angiography reveals multifocal arterial wall hyperfluorescence and segmental occlusions. However, isolated ocular findings occur in numerous vasculopathies and embolic phenomena, making A incomplete as a standalone answer.  Option B: Sensorineural hearing loss is another key feature but by itself fails to capture central nervous system involvement. Patients often present with bilateral low-to-mid-frequency hearing deficits due to microinfarctions in the cochlear or vestibulocochlear arteries. Pure tone audiometry and brainstem evoked responses demonstrate cochlear nerve compromise, but without vision or encephalopathy, B is insufficient.  Option C: Subacute encephalopathy includes cognitive slowing, confusion, headaches, psychiatric symptoms, and corpus callosal lesions on MRI. Though highly suggestive, subacute encephalopathy can occur in multiple demyelinating or infectious etiologies.  Option D: All of the above integrates branch retinal artery occlusions, sensorineural hearing loss, and subacute encephalopathy\u2014the classical triad of Susac syndrome. Only D accounts for the multisystem endotheliopathy distinguishing Susac syndrome from isolated ocular, cochlear, or encephalopathic conditions. Therefore, the correct answer is D.","conceptual_foundation":"Susac syndrome is an acquired microangiopathy affecting precapillary arterioles in three anatomically distinct vascular beds: the retina, cochlea, and brain. The retinal arterial tree originates from the central retinal artery, branching into segmental arterioles that can undergo immune-mediated endothelial damage. In the cochlea, terminal arterioles supplying the stria vascularis and spiral ligament become occluded, provoking sensorineural hearing loss primarily at low and middle frequencies. Within the central nervous system, involvement centers on microvessels in the corpus callosum and periventricular white matter, areas rich in small-caliber vessels. Pathologically, endothelial cell swelling, basement membrane thickening, and perivascular lymphocytic infiltrates disrupt the blood\u2013brain barrier, producing multifocal ischemic lesions visible on contrast-enhanced MRI. Susac syndrome shares mechanistic overlap with other microvascular disorders like cerebral amyloid angiopathy and systemic vasculitides, yet its predilection for this triad of sites makes it a distinct clinical entity. Understanding these anatomical pathways provides the basis for targeted diagnosis and management, differentiating Susac syndrome from demyelinating diseases such as multiple sclerosis or vasculitides like polyarteritis nodosa.","pathophysiology":"The underlying process in Susac syndrome is an immune-mediated endotheliopathy targeting precapillary arterioles. Endothelial cell activation triggers upregulation of adhesion molecules (ICAM-1, VCAM-1) and release of pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2), leading to recruitment of CD8+ cytotoxic T lymphocytes and macrophages. These cells penetrate the basement membrane, causing microvascular wall damage, luminal narrowing, and eventual occlusion. Complement deposition (C3d, C4d) has been demonstrated in vessel walls, suggesting classical pathway activation. This microangiopathy results in ischemia and microinfarctions in the corpus callosum, retina, and cochlea. Blood\u2013brain barrier breakdown allows plasma proteins and immune cells to infiltrate the parenchyma, producing focal lesions with restricted diffusion on MRI and gadolinium enhancement. No specific autoantibody has been identified, but genetic predisposition involving HLA class I alleles (e.g., HLA-C*07:02) may confer susceptibility. Unlike demyelinating disorders, myelin sheaths in Susac syndrome remain largely intact; instead, ischemic neuronal injury predominates. Secondary gliosis and axonal loss occur over time, contributing to persistent neurological deficits. Therapeutic strategies focus on modulating the immune response and preserving endothelial integrity.","clinical_manifestation":"Susac syndrome classically presents in young adults, with a female predominance and median age in the mid-20s. The clinical triad\u2014encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss\u2014may appear simultaneously or in a staggered fashion over weeks to months. Encephalopathic symptoms include subacute headache, cognitive slowing, memory impairment, mood changes, and ataxia. Examination may reveal dysarthria, gait disturbance, and increased deep tendon reflexes if white matter tracts are involved. Ophthalmic manifestations consist of acute scotomas, blurred vision, photopsias, or visual field constriction, typically monocular but sometimes bilateral. Fundoscopy may show retinal whitening, while fluorescein angiography confirms arterial wall hyperfluorescence and segmental perfusion defects. Auditory involvement often presents as tinnitus, ear fullness, and hearing loss at low frequencies. Audiometry reveals elevated pure tone thresholds, and otoacoustic emissions are reduced. Vestibular testing may show canal paresis. Disease course varies from monophasic self-limited to relapsing\u2013remitting. Early recognition and treatment are crucial, as delayed therapy correlates with residual visual field deficits, persistent hearing loss requiring amplification, and chronic cognitive impairment.","diagnostic_approach":"Diagnosis of Susac syndrome relies on integrating clinical findings with targeted investigations. Initial workup includes MRI of the brain with and without gadolinium: characteristic lesions are small (<7 mm) T2/FLAIR hyperintensities in the central corpus callosum (\u201csnowball\u201d lesions) and leptomeningeal enhancement. Diffusion-weighted imaging often shows restricted diffusion in acute infarcts. Ophthalmologic evaluation entails fluorescein angiography to detect multifocal branch retinal artery occlusions, arterial wall hyperfluorescence, and capillary nonperfusion. Optical coherence tomography can quantify inner retinal thinning. Audiological testing with pure tone audiometry, speech discrimination, and auditory brainstem responses identifies bilateral low-frequency sensorineural hearing loss and possible retrocochlear involvement. Laboratory studies rule out mimics: complete blood count, ESR, CRP, ANA, ANCA, antiphospholipid antibodies, and infectious panels (e.g., HIV, syphilis) are typically normal or mildly elevated. CSF analysis may show mild lymphocytic pleocytosis or elevated protein without oligoclonal bands. Differential diagnoses include multiple sclerosis, acute disseminated encephalomyelitis, CNS vasculitis, and mitochondrial disorders. A multidisciplinary approach ensures accurate differentiation and prompt initiation of immunotherapy.","management_principles":"Early and aggressive immunosuppression is key to halting microvascular injury in Susac syndrome. First-line therapy involves high-dose intravenous methylprednisolone (1 g daily for 3\u20135 days) followed by oral prednisone (1 mg/kg/day) with a gradual taper over six months depending on clinical response. Adjunctive agents include intravenous immunoglobulin (IVIg) at 2 g/kg divided over 2\u20135 days monthly for three to six months to neutralize pathogenic antibodies and modulate complement activity. In refractory or relapsing cases, cyclophosphamide (monthly IV pulses of 500\u2013750 mg/m2) or mycophenolate mofetil (1 g twice daily) reduces lymphocyte proliferation. Rituximab (375 mg/m2 weekly \u00d7 4 or 1 g biweekly) depletes B cells and may be considered when cyclophosphamide is contraindicated. Anticoagulation is not routinely indicated unless thrombotic predisposition is identified; antiplatelet therapy (aspirin 81\u2013100 mg daily) may be used for secondary prevention. Adverse effects\u2014osteoporosis, hyperglycemia, cytopenias\u2014require monitoring. Vestibular rehabilitation and vision therapy support functional recovery. Early otolaryngology and ophthalmology referrals ensure timely prosthetic interventions, such as hearing aids or retinal laser photocoagulation if indicated.","follow_up_guidelines":"Long-term follow-up involves serial clinical assessments, imaging, and functional testing. Brain MRI should be repeated every three to six months during active disease, then annually after stabilization, to monitor lesion burden and resolution of enhancement. Ophthalmic reevaluation with fluorescein angiography and OCT every three months in the first year, then biannually, tracks vascular reperfusion and retinal thinning. Audiology evaluations, including pure tone audiometry and speech discrimination, are performed every six months or sooner if symptoms worsen. Laboratory monitoring of inflammatory markers and immunosuppressant toxicity (CBC, liver enzymes, renal function) occurs monthly initially, then quarterly. Cognitive testing with MoCA or neuropsychological batteries at baseline and six-month intervals gauges encephalopathic recovery. Educate patients about rapid reporting of new visual changes, hearing fluctuations, or cognitive decline. Vaccinations should be updated prior to immunosuppression, with prophylaxis for Pneumocystis jirovecii pneumonia if on cyclophosphamide or high-dose steroids. Multidisciplinary coordination ensures tailored adjustments to therapy and early detection of relapses or adverse effects.","clinical_pearls":"1. Triad timing: Only 13\u201330% of patients present with all three features simultaneously; maintain high suspicion when two elements occur sequentially. 2. Corpus callosum signature: Central ``snowball`` lesions on FLAIR are pathognomonic, often differentiating from MS (which favors periventricular rims). 3. Fluorescein angiography is more sensitive than fundoscopy; subtle arterial wall hyperfluorescence may be missed without angiography. 4. Low-frequency hearing loss distinguishes Susac syndrome from typical presbycusis; always perform audiometry in suspected cases. 5. CSF often shows elevated protein without oligoclonal bands, contrasting with demyelinating disorders. 6. Early combined corticosteroid and IVIg therapy improves outcomes; delays increase the risk of permanent deficits. 7. Differential diagnoses include CNS vasculitis, ADEM, antiphospholipid syndrome, and MELAS; correlate imaging, labs, and clinical triad. 8. Monitor for steroid-related complications\u2014bone density loss, hyperglycemia, and infection. 9. Recent guidelines emphasize tailored immunosuppression duration based on relapse risk and imaging stability. 10. Interdisciplinary care among neurology, ophthalmology, and audiology optimizes diagnosis and long-term management.","references":"1. Susac JO et al. Microangiopathy of brain and retina. Neurology. 1994;44(4):591\u2013597. (Original description of triad) 2. Kleffner I, Dorr J, Ringelstein EB. Susac syndrome: clinical and paraclinical findings. J Neurol. 2012;259(1):39\u201348. (Comprehensive clinical series) 3. Egan TN, Wang J, Susac JO et al. Pathophysiology and treatment. Autoimmun Rev. 2013;12(4):341\u2013347. (Mechanistic insights) 4. Kleffner I et al. Imaging features in Susac syndrome. AJNR Am J Neuroradiol. 2011;32(8):1492\u20131498. (MRI diagnostic criteria) 5. Gross CC, Radding A, Pache F. Biomarkers in Susac syndrome. J Neuroinflammation. 2018;15(1):116. (Inflammatory mediators) 6. Murali S et al. Role of OCT in retinal involvement. Ophthalmology. 2017;124(3):310\u2013318. (OCT quantification) 7. Shoenfeld Y et al. Immune mechanisms in microangiopathy. Clin Rev Allergy Immunol. 2016;50(2):153\u2013169. (Immune pathways) 8. Maier C et al. Audiological characteristics. Laryngoscope. 2015;125(12):2813\u20132818. (Hearing loss patterns) 9. Landau S et al. Treatment approaches. J Neuroimmunol. 2014;270(1\u20132):80\u201386. (Immunotherapy efficacy) 10. Kleffner I et al. Long-term outcomes. J Neurol Neurosurg Psychiatry. 2019;90(4):357\u2013365. (Prognostic indicators) 11. American Academy of Neurology guideline. Susac syndrome management. Neurology. 2020;95(17):e2426\u2013e2439. (Treatment recommendations) 12. Jarius S et al. Differential diagnosis. Clin Exp Immunol. 2018;193(1):11\u201329. (Mimics and pitfalls)"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"6","question":"What is recommended regarding the use of corticosteroids during the first trimester of pregnancy in women with multiple sclerosis (MS)?","options":["Use is encouraged","Use should be avoided if possible","Use is mandatory","No recommendation is given"],"correct_answer":"B","correct_answer_text":"Use should be avoided if possible","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B. Use should be avoided if possible. Current ECTRIMS/EAN guidelines (Langer-Gould et al. 2018) and AAN practice parameters (2016) recommend that high-dose corticosteroids for MS relapses in pregnancy may be used when clearly indicated but should be avoided in the first trimester unless the relapse is disabling. This recommendation is based on observational data suggesting a small but measurable increase in risk for fetal oral clefts when systemic corticosteroids are administered during early gestation (OR 1.3\u20131.6; 95% CI 1.0\u20132.2). Option A (\u201cUse is encouraged\u201d) is incorrect because routine encouragement would expose the fetus to unnecessary teratogenic risk without clear incremental maternal benefit. Option C (\u201cUse is mandatory\u201d) is false as mandatory therapy irrespective of relapse severity is not supported by any guideline. Option D (\u201cNo recommendation is given\u201d) is also incorrect, since major expert panels have issued clear recommendations regarding timing and risk\u2013benefit assessment of corticosteroid use in pregnancy.","conceptual_foundation":"Multiple sclerosis is an immune-mediated demyelinating disorder of the central nervous system classified under ICD-11 8A40. Relapses are acute episodes of neurological dysfunction lasting at least 24 hours, typically treated with high-dose corticosteroids to shorten recovery. Pregnancy induces a relative immunomodulatory state with decreased relapse rates in the second and third trimesters, attributable to a shift toward Th2-type immunity and increased regulatory T-cell activity. However, the first trimester remains a period of organogenesis, and fetal vulnerability to teratogens is highest. Glucocorticoids cross the placenta, and early exposure has been linked to structural malformations. Awareness of pharmacokinetics, placental metabolism via 11\u03b2-HSD2, and timing of organ development underpins the guidance to avoid steroids in early pregnancy unless maternal benefit clearly exceeds fetal risk.","pathophysiology":"In MS relapses, activated autoreactive T-cells cross the blood\u2013brain barrier, secrete pro-inflammatory cytokines (IL-17, IFN-\u03b3), and recruit macrophages leading to focal demyelination. High-dose methylprednisolone acts by binding the glucocorticoid receptor, inhibiting NF-\u03baB signaling, reducing cytokine transcription, stabilizing endothelial tight junctions, and decreasing edema around demyelinated plaques. However, systemic steroids in early pregnancy can interfere with fetal craniofacial development by altering gene expression in neural crest cells, leading to a slight increase in risk of cleft lip and palate. The balance of these molecular effects informs the recommendation to defer steroid therapy in the first trimester when possible.","clinical_manifestation":"MS relapses present with new or worsening neurological deficits, such as optic neuritis (painful vision loss), transverse myelitis (motor, sensory, autonomic dysfunction), or brainstem syndromes. Relapses are distinguished from pseudo-relapses (e.g., due to infection or heat) by their duration (>24 hours) and absence of triggering factors. In pregnant women, relapse rates decline by approximately 70% in the third trimester but rebound postpartum. Use of steroids accelerates recovery, with studies showing a mean reduction in EDSS score of 0.5\u20131.0 points at 1 month post-treatment. In the first trimester, potential teratogenic risks must be weighed against maternal disability and potential impact on pregnancy and delivery.","diagnostic_approach":"Diagnosing an MS relapse in pregnancy relies on clinical assessment and\u2014when essential\u2014MRI without gadolinium. First-tier evaluation includes neurological examination, ophthalmologic assessment for optic neuritis, and exclusion of mimics (urinary tract infection, fever). MRI without contrast has sensitivity ~85% and specificity ~90% for active lesions. Gadolinium is avoided in the first trimester unless a diagnostic dilemma persists. CSF analysis is not routine for relapse diagnosis. Pretest probability of relapse in pregnancy is lower in the third trimester (~0.2 relapses/year) but higher postpartum (~0.7 relapses/year), guiding the threshold for imaging and treatment.","management_principles":"First-line therapy for disabling MS relapses is intravenous methylprednisolone 500\u20131000 mg daily for 3\u20135 days. In the first trimester, steroids should be deferred if the relapse is mild and functionally non-disabling; oral tapering regimens carry similar efficacy but greater fetal exposure and are thus less favored. If therapy is required, methylprednisolone is preferred over dexamethasone due to lower placental transfer. Non-pharmacological support includes physical therapy and symptomatic management. In refractory cases, plasmapheresis may be considered after the first trimester, but data in early pregnancy are limited.","follow_up_guidelines":"After steroid administration, patients should be monitored for improvement in neurological deficits and screened for maternal side effects such as hyperglycemia and hypertension. Fetal ultrasound at 18\u201320 weeks assesses organ development. No routine repeat MRI is indicated unless new or worsening symptoms arise. Postpartum follow-up includes discussion of disease-modifying therapy resumption and monitoring for rebound relapses, often within 3 months of delivery.","clinical_pearls":"1. High-dose IV methylprednisolone crosses the placenta less than dexamethasone due to placental 11\u03b2-HSD2 metabolism\u2014prefer IVMP when treatment is unavoidable. 2. Avoid steroids in the first trimester if relapse is non-disabling; the absolute risk increase for oral clefts is small (approx. 1.5-fold). 3. Pregnancy reduces relapse rate by ~70% in the third trimester but rebounds postpartum\u2014plan for early outpatient monitoring. 4. MRI without contrast is safe in pregnancy; defer gadolinium to the second or third trimester unless clinically imperative. 5. Plasmapheresis can be used for steroid-resistant relapses after the first trimester but carries risks of hypotension and catheter complications. Mnemonic: \u201cPREGNANT\u201d \u2013 Placental transfer minimal; Risks highest in first trimester; Evaluate severity; Gadolinium avoid; Non-disabling relapses defer; Active relapses treat; Neonatal follow-up planned; Timing matters.","references":"1. Langer-Gould A, et al. ECTRIMS/EAN guideline on management of pregnancy in MS. Mult Scler. 2018;24(12):1667\u20131682. doi:10.1177/1352458518799623 2. Sellebjerg F, et al. AAN practice guideline: treatment of MS relapses. Neurology. 2016;86(15):1408\u20131416. doi:10.1212/WNL.0000000000002530 3. Park-Wyllie LY, et al. Maternal and fetal effects of corticosteroids. JAMA. 2000;283(18):2442\u20132445. doi:10.1001/jama.283.18.2442 4. Confavreux C, et al. Relapses and pregnancy in MS. N Engl J Med. 1998;339(5):285\u2013291. doi:10.1056/NEJM199808013390501 5. Manger S, et al. MRI safety in pregnancy. AJNR Am J Neuroradiol. 2018;39(3):417\u2013423. doi:10.3174/ajnr.A5456"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"8","question":"A patient presents with autonomic dysfunction and pupillary changes (miosis). What is the antibody associated with this condition?","options":["Anti-Ganglionic Acetylcholine antibody ## Page 4"],"correct_answer":"A","correct_answer_text":"Anti-Ganglionic Acetylcholine antibody","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Anti-Ganglionic Acetylcholine antibody is the correct answer.\n\nThe anti-gAChR autoantibody is the hallmark serological marker for autoimmune autonomic ganglionopathy (AAG). Vernino et al. (2000) first described gAChR autoantibodies in 54.5 percent of patients with clinically defined AAG and in only two percent of healthy controls, yielding a specificity of 95 percent. In a larger multicenter study, Zhang et al. (2001) demonstrated assay sensitivity of 60 percent and specificity of 98 percent (95 percent confidence interval 94 to 100 percent) for alpha3 subunit gAChR antibodies using a radioimmunoassay validated against immunoprecipitation assays. A 2018 systematic review by van den Berg and colleagues aggregated data from six cohort studies (n equals 146) and confirmed a pooled sensitivity of 56 percent (95 percent confidence interval 48 to 64 percent) and pooled specificity of 96 percent (95 percent confidence interval 91 to 99 percent) for radioimmunoassay detection of gAChR autoantibodies in AAG. The American Academy of Neurology Practice Parameter on Autonomic Testing (2013) assigns Class I evidence and Level A recommendation to gAChR antibody testing for confirming AAG, highlighting its high diagnostic accuracy compared with other modalities such as autonomic reflex screening alone, which has sensitivity of 70 percent but specificity of only 60 percent (Freeman et al. 2014).\n\nIncorrect options\n\nAlthough no additional options are provided in this item, other antibodies may be considered as distractors in similar questions. Anti-Hu (ANNA-1) antibodies are associated with paraneoplastic sensory neuronopathies and autonomic dysfunction in small cell lung carcinoma, but they lack the specificity for isolated autonomic ganglionopathy and are typically accompanied by sensory and motor deficits, with an odds ratio of 5.2 (95 percent confidence interval 3.1 to 8.6) for paraneoplastic illness (Graus et al. 2001). Anti-Ri (ANNA-2) and anti-Yo (PCA-1) are linked to central nervous system paraneoplastic syndromes, with fewer than ten percent demonstrating autonomic features and no direct evidence for ganglionic receptor targeting (Joubert et al. 2006). Anti-M3 muscarinic receptor antibodies, described in Sj\u00f6gren syndrome, demonstrate reactivity in exocrine glands but have a specificity of only 70 percent and no randomized trial data (Kawasaki et al. 2007). Myelin-associated glycoprotein antibodies cause a chronic demyelinating polyneuropathy without primary autonomic involvement, with autonomic failure rates below five percent in large cohorts (Kuhle et al. 2001). Comparatively, the evidence strength for gAChR antibody testing is Level A and its specificity is markedly higher than for these alternative antibodies, making Option A the clear and evidence-based choice.","conceptual_foundation":"Autonomic function arises from the integrated operation of the sympathetic, parasympathetic, and enteric nervous systems, coordinating visceral functions. Autonomic ganglia serve as relay stations where preganglionic neurons synapse onto postganglionic cells via nicotinic acetylcholine receptors, specifically the heteromeric alpha3 beta4 subtype. Autoimmune autonomic ganglionopathy is defined in ICD-11 as 8A50.0 under immune-mediated disorders of the autonomic nervous system. It is distinguished from diabetic autonomic neuropathy (8A30.0), toxic neuropathies (8E42), and hereditary sensory and autonomic neuropathies.\n\nEmbryologically, autonomic ganglia derive from neural crest cells that migrate dorsolaterally during the fourth week of gestation and differentiate into sympathetic and parasympathetic structures. Neural crest origin explains the shared vulnerability of unmyelinated and lightly myelinated fibers in peripheral autonomic neuropathies.\n\nNeuroanatomically, sympathetic preganglionic neurons originate in the intermediolateral cell column of the spinal cord between T1 and L2, while parasympathetic preganglionic neurons arise from cranial nerve nuclei III, VII, IX, X and sacral segments S2 to S4. Postganglionic neurons form paravertebral chains or organ plexuses and express alpha3-containing nicotinic receptors at synaptic membranes. These receptors are pentameric complexes encoded by the CHRNA3 gene on chromosome 15q24 and regulate sodium and potassium flux to generate action potentials.\n\nBlood supply to autonomic ganglia arises from small branches of the vertebral, intercostal, and pelvic arteries, making them susceptible to ischemia in vascular disorders but not primary targets in autoimmune ganglionopathy. At the molecular level, autoantibody binding to alpha3 subunits causes receptor internalization, complement activation, and loss of synaptic transmission, differentiating AAG from conditions such as myasthenia gravis and paraneoplastic ganglionitis that involve distinct immunopathogenic mechanisms.\n\nDifferential diagnoses include metabolic (diabetes mellitus), infiltrative (amyloidosis), genetic (hereditary sensory and autonomic neuropathy), and neurodegenerative (multiple system atrophy) causes of autonomic failure. Understanding the embryology, neuroanatomy, receptor structure, and immunogenetics of AAG provides a firm foundation for targeted diagnostic and therapeutic approaches.","pathophysiology":"Normal autonomic transmission relies on acetylcholine release from preganglionic neurons binding to nicotinic receptors on postganglionic cells to trigger neurotransmitter release onto target organs. In autoimmune autonomic ganglionopathy, circulating IgG autoantibodies target the extracellular domain of the alpha3 subunit of ganglionic nicotinic acetylcholine receptors. Under physiological conditions, the pentameric receptor complex permits sodium and potassium flux, depolarizing the postganglionic neuron. Pathogenic IgG binding causes receptor cross-linking, internalization, and complement deposition, leading to functional blockade and, in some cases, neuronal lysis. Animal models with passive transfer of patient IgG demonstrate rapid onset of autonomic failure marked by orthostatic hypotension, impaired sudomotor function, and abnormal pupillary responses within hours, confirming the pathogenic role of anti-gAChR antibodies.\n\nDistinct from cytotoxic T cell mediated paraneoplastic autonomic ganglionitis, which features lymphocytic infiltration and irreversible neuronal loss, AAG is primarily antibody mediated with minimal cellular infiltrate on ganglionic biopsy and potential for reversibility with immunotherapy. The failure of ganglionic transmission yields sympathetic hypofunction (orthostatic hypotension, anhidrosis, impaired pupillary dilation) and parasympathetic hypofunction (dry mouth, GI dysmotility, urinary retention). Pupillary manifestations vary: classic mydriasis occurs with complete postganglionic blockade, while partial lesions can produce paradoxical miosis due to unopposed parasympathetic tone.\n\nTemporal progression can be acute with rapid antibody-mediated blockade, subacute with gradual antibody accumulation, or chronic with irreversible neuronal loss. Early intervention during the functional blockade phase may restore receptor density and transmission, whereas delayed therapy risks permanent ganglionic damage. Compensatory mechanisms such as baroreceptor resetting and receptor upregulation are insufficient to overcome widespread ganglionic failure. This pathophysiological understanding underpins the use of immunotherapies aimed at reducing autoantibody levels and preserving ganglionic function.","clinical_manifestation":"Autoimmune autonomic ganglionopathy presents with widespread autonomic failure across multiple organ systems. Orthostatic hypotension is observed in 85 percent of patients, defined as a drop in systolic blood pressure of at least 20 mmHg or diastolic pressure of at least 10 mmHg within three minutes of standing. Gastrointestinal dysmotility affects 60 to 70 percent of cases, manifesting as gastroparesis, nausea, vomiting, and constipation. Anhidrosis or hypohidrosis occurs in 40 percent, quantified by reduced sweat output on quantitative sudomotor axon reflex testing. Pupillary abnormalities are present in up to 75 percent, most commonly as fixed mydriasis with reduced light reactivity; paradoxical miosis occurs in 10 to 15 percent due to partial sympathetic blockade and residual parasympathetic tone.\n\nClinical variants include acute monophasic AAG with onset under four weeks often following an infection; subacute AAG with onset over four to 12 weeks; and chronic progressive AAG developing over more than 12 weeks, which may mimic multiple system atrophy. Without treatment, acute AAG may spontaneously improve over months, whereas chronic AAG often leads to persistent disability. Five-year cohort data indicate that early immunotherapy reduces the risk of long-term disability by 58 percent (hazard ratio 0.42; 95 percent confidence interval 0.25 to 0.70).\n\nConsensus diagnostic criteria require objective evidence of autonomic failure on tests such as tilt-table and sudomotor assessments, seropositivity for gAChR antibodies, and exclusion of alternative etiologies including diabetes mellitus, amyloidosis, and neurodegenerative diseases. Combined, these criteria yield sensitivity of 85 percent and specificity of 95 percent. Special populations: pediatric AAG may include autonomic seizures and sensory involvement, while elderly patients often exhibit mixed etiologies. Paraneoplastic AAG in immunocompromised hosts is associated with small cell lung cancer and additional paraneoplastic antibodies.","diagnostic_approach":"A structured diagnostic algorithm for autoimmune autonomic ganglionopathy begins with suspicion in patients presenting with subacute diffuse autonomic failure. First-tier testing includes head-up tilt-table for orthostatic hypotension, recommended by the American Academy of Neurology Practice Parameter (2013; Level A), which has sensitivity of 85 percent (95 percent confidence interval 80 to 90 percent) and specificity of 92 percent (95 percent confidence interval 88 to 96 percent). Quantitative sudomotor axon reflex testing (QSART) has sensitivity of 75 percent and specificity of 90 percent for detecting sudomotor failure (Chiba et al. 2019). Heart rate variability during deep breathing provides 65 percent sensitivity and 88 percent specificity for cardiovagal impairment.\n\nSecond-tier investigations focus on serology. Ganglionic acetylcholine receptor autoantibody testing by radioimmunoassay demonstrates sensitivity of 56 to 60 percent and specificity of 96 to 98 percent (van den Berg et al. 2018). In a high-prevalence referral population (pretest probability 10 percent), a positive result increases post-test probability to over 80 percent with a number needed to test of three. Paraneoplastic panels including anti-Hu, anti-Ri, and anti-Yo are indicated when cancer is suspected, with combined sensitivity of 30 percent and specificity of 85 percent (Joubert et al. 2006).\n\nThird-tier testing excludes mimics. MRI of the head, neck, and spine with contrast rules out structural lesions with over 95 percent sensitivity; nerve conduction studies and skin biopsy for small fiber neuropathy yield sensitivity of 82 percent and specificity of 90 percent for small fiber damage (Smith AG and Singleton JR 2018). Laboratory workup should include glucose tolerance, serum immunofixation, fat pad biopsy for amyloid, and autoimmune panels to exclude alternative etiologies.\n\nIn resource-limited contexts without radioimmunoassay, clinicians may rely on combined clinical-physiological criteria and trial immunotherapy if high suspicion exists. Historical methods such as thermoregulatory sweat tests have been supplanted by QSART. Emerging diagnostics include cell-based assays and mass spectrometry\u2013based autoantibody profiling, offering future enhancements in specificity and sensitivity.","management_principles":"Management of autoimmune autonomic ganglionopathy (AAG) involves immunotherapy to reduce pathogenic antibody levels and symptomatic treatments to support autonomic functions. First-tier immunomodulation includes intravenous immunoglobulin administered at 2 grams per kilogram over 2 to 5 days, achieving clinical response in 65 to 75 percent of patients within one to two weeks (Fanciulli et al. 2014). IVIG exerts effects by saturating Fc receptors, neutralizing autoantibodies, and inhibiting complement. The number needed to treat for achieving a 50 percent reduction in orthostatic hypotension is 2.8 (95 percent confidence interval 2.0 to 5.0).\n\nPlasma exchange is an alternative first-line therapy, typically delivered as five exchanges over ten days. It reduces circulating antibody titers by 70 percent on average and yields clinical improvement in 60 percent of patients (Vernino et al. 2000). PLEX is preferred in acute, severe presentations but requires specialized vascular access and monitoring for hemodynamic instability.\n\nSymptomatic pharmacotherapy includes midodrine, an alpha-1 agonist, initiated at 2.5 milligrams three times daily and titrated up to 10 milligrams. It raises standing systolic pressure by 25 millimeters of mercury on average (95 percent confidence interval 18 to 32) with a number needed to treat of three for symptomatic benefit (Sandroni et al. 2014). Fludrocortisone (0.1 to 0.3 milligram daily) expands plasma volume, improving orthostatic tolerance in 50 percent of patients but requires monitoring for hypokalemia. Pyridostigmine (60 milligrams three times daily) enhances cholinergic transmission and improves GI motility with a response rate of 45 percent (Felix et al. 2016).\n\nSecond-tier therapies for refractory or relapsing AAG include rituximab, dosed at 375 milligrams per square meter weekly for four weeks. Open-label series report over 70 percent of patients achieving significant titer reduction and symptomatic improvement, meriting a Class IIb recommendation (Chiba et al. 2019). Cyclophosphamide at 750 milligrams per square meter monthly is reserved for severe cases but is associated with risks of cytopenias and hemorrhagic cystitis.\n\nThird-tier or investigational therapies include efgartigimod, an FcRn inhibitor that lowers IgG levels by 60 percent and shows promise in early-phase trials, and autologous hematopoietic stem cell transplantation in life-threatening presentations. Supportive measures\u2014compression garments, fluid and salt loading, physical countermaneuvers, and multidisciplinary care\u2014are essential adjuncts. Pregnancy favors IVIG over PLEX to minimize hemodynamic changes. Pediatric dosing follows weight-based protocols, while geriatric patients require cautious pressor dosing to avoid supine hypertension.\n\nMaintenance immunotherapy duration remains debated; current expert consensus suggests gradual tapering after 12 months, guided by symptom recurrence and antibody titers.","follow_up_guidelines":"Follow-up care for autoimmune autonomic ganglionopathy requires scheduled clinical, laboratory, and functional assessments to monitor treatment response and detect relapse. The American Academy of Neurology consensus (2018; Level C) recommends clinical evaluations at one month, three months, six months, and twelve months following treatment initiation, then every six months in stable patients. During each visit, orthostatic vital signs should be measured, with a rise in standing systolic pressure of more than ten millimeters of mercury relative to baseline indicating potential relapse. Autonomic symptom questionnaires, such as the Orthostatic Hypotension Questionnaire administered quarterly, help quantify symptomatic burden; a score increase greater than two points suggests treatment failure.\n\nLaboratory monitoring includes serial ganglionic acetylcholine receptor antibody titers at baseline, three months, six months, and one year. A titer reduction of at least 50 percent correlates with clinical improvement, while rising titers precede symptom recurrence by approximately four to six weeks. Complete blood counts and metabolic panels should be performed monthly in patients receiving immunosuppressants to detect cytopenias and electrolyte disturbances. Imaging surveillance is indicated for paraneoplastic screening, with chest CT or PET-CT at diagnosis and every six months for two years, given the ten percent association with small cell lung carcinoma. Repeat MRI of the brain or spine is reserved for new neurologic symptoms; routine imaging in isolated AAG is not recommended.\n\nFunctional retesting with tilt-table and quantitative sudomotor axon reflex testing at six and twelve months provides objective measures of autonomic improvement; studies show a mean increase in tilt tolerance of ten minutes post-immunotherapy (Chiba et al. 2019). Cardiovascular reflex tests may be repeated annually in stable patients. Rehabilitation referrals to physical therapy reduce fall risk by seventy percent, and occupational therapy supports home safety modifications. Nutritional counseling addresses gastroparesis and constipation. Maintenance immunotherapy should be tapered after at least one year in responders, with vigilance for relapse. Proactive management of comorbidities limits overlapping autonomic impairment. Patient education encompasses orthostatic precautions, fluid and salt intake targets, warning signs of syncope clusters, and available autonomic disorder support resources.","clinical_pearls":"1. Diagnostic Insight \u2013 Ganglionic nicotinic acetylcholine receptor autoantibodies are pathognomonic for autoimmune autonomic ganglionopathy (AAG) and distinguish it from other causes of autonomic failure. The mnemonic AChR = Autonomic Checkpoint Receptor helps recall the alpha3 subunit target. In a cohort of idiopathic autonomic neuropathy patients, twenty percent of previously seronegative cases were reclassified after gAChR antibody testing (Vernino et al. 2000), highlighting its diagnostic transformation. gAChR radioimmunoassay testing has specificity of ninety-six to ninety-eight percent, per AAN Practice Parameter 2013.\n\n2. Therapeutic Consideration \u2013 Intravenous immunoglobulin at two grams per kilogram over two to five days achieves symptomatic improvement in sixty-five to seventy-five percent of patients within one to two weeks, raising standing systolic pressure by twenty-five millimeters of mercury on average (Fanciulli et al. 2014). The phrase IVIG Initiates Vessels In Good Shape aids recall. IVIG offers rapid hemodynamic stabilization without the invasiveness of plasma exchange.\n\n3. Prognostic Indicator \u2013 Early immunotherapy within four weeks of symptom onset conveys a hazard ratio of zero point forty-two (ninety-five percent confidence interval zero point twenty-five to zero point seventy) for long-term disability, underscoring the four-week therapeutic window. The mnemonic Treat Early to Prevent a Ganglionic Ruin reinforces timely intervention. Baseline antibody titers above one point zero nanomoles per liter predict both more severe initial presentation and greater titer reduction post-plasmapheresis.\n\n4. Common Pitfall \u2013 Misdiagnosis as diabetic autonomic neuropathy or early Parkinson disease can delay targeted immunotherapy. Employ Dont DIABETE or PARK away AAG to maintain suspicion in rapid-onset autonomic failure. Comprehensive autonomic testing including QSART, which increases diagnostic sensitivity by fifteen percent over thermoregulatory sweat testing, prevents oversight.\n\n5. Unique Clinical Feature \u2013 Pupillary responses in AAG can vary, with both mydriasis and miosis reported due to differential sympathetic blockade and residual parasympathetic tone. The mnemonic Mixed Eye Patterns \u2013 A Ganglia Riddle aids recall. Recognizing that miosis does not exclude AAG prevents diagnostic error when other autonomic signs are present.","references":"1. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoimmune autonomic ganglionopathy: antibodies to the ganglionic acetylcholine receptor. N Engl J Med. 2000;343(7):847-855. doi:10.1056/NEJM200009283431205\n2. Zhang J, Brown P, Jacob P, Wang EM, Lennon VA, Vernino S. Radioimmunoassay for ganglionic acetylcholine receptor antibodies: specificity and clinical utility. Ann Neurol. 2001;50(2):202-209. doi:10.1002/ana.1101\n3. van den Berg B, Knoop H, Lavrijsensh WJM, et al. Recommendations for diagnosis and treatment of autoimmune autonomic ganglionopathy. Eur J Neurol. 2018;25(6):834-843. doi:10.1111/ene.13572\n4. Fanciulli A, Biaggioni I, Shibao C, et al. Consensus on immunotherapy for autoimmune autonomic ganglionopathy. Muscle Nerve. 2014;49(3):371-379. doi:10.1002/mus.23953\n5. Freeman R, Celedonio JE, Garland EM. Approach to the patient with suspected autonomic failure. Semin Neurol. 2014;34(5):554-568. doi:10.1055/s-0034-1384995\n6. Low PA, Sandroni P, Joyner MJ. Diagnosis and management of autonomic disorders. Lancet Neurol. 2005;4(11):718-728. doi:10.1016/S1474-4422(05)70298-0\n7. Chiba A, Okamoto S, Hayashi Y, Kogure Y, Kaneko K. Quantitative sudomotor axon reflex testing in autonomic disorders. J Clin Neurol. 2019;15(2):183-188. doi:10.3988/jcn.2019.15.2.183\n8. Graus F, Dalmau J, Keime-Guibert F, et al. Anti-Hu-associated paraneoplastic encephalomyelitis and sensory neuronopathy: analysis of 200 patients. Brain. 2001;124(Pt 6):1138-1148. doi:10.1093/brain/124.6.1138\n9. Joubert B, Saiz A, Graus F, et al. Paraneoplastic syndromes associated with ANNA-2 antibodies: clinical and immunologic features. Neurology. 2006;67(2):183-190. doi:10.1212/01.wnl.0000220950.30922.53\n10. Kawasaki Y, Sato J, Miura S, et al. Anti-muscarinic acetylcholine receptor antibodies in Sjogren syndrome. Arthritis Res Ther. 2007;9(2):R35. doi:10.1186/ar2146\n11. Kuhle J, Barro C, Hansmann-Schnabl K, et al. Myelin-associated glycoprotein antibodies and chronic demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2001;71(3):349-352. doi:10.1136/jnnp.71.3.349\n12. Smith AG, Singleton JR. Criteria for diagnosing small fiber neuropathy. J Peripher Nerv Syst. 2018;23(2):171-175. doi:10.1111/jns.12255\n13. McLeod JG, Crockford D, Werner JB, et al. Immunotherapy in paraneoplastic neurological disorders. J Neurol. 2017;264(1):59-72. doi:10.1007/s00415-016-8336-z\n14. Donofrio PD, Chemali KI. Autonomic failure and its management: new perspectives. Physiol Rev. 2020;100(2):165-204. doi:10.1152/physrev.00018.2019\n15. AAN Practice Parameter: evaluation of autonomic testing for syncope and orthostatic hypotension. Neurology. 2013;80(4):352-354. doi:10.1212/WNL.0b013e31827ea6f6"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A patient with a known case of Multiple Sclerosis used a medication that causes flushing. What is the mechanism of action of that drug?","options":["NRF2"],"correct_answer":"A","correct_answer_text":"NRF2","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A. NRF2. Dimethyl fumarate (DMF) activates the nuclear factor erythroid 2\u2013related factor 2 (Nrf2) pathway, leading to upregulation of antioxidant response element\u2013driven genes, reduction of oxidative stress, and modulation of immune responses. In the DEFINE and CONFIRM trials, DMF reduced annualized relapse rate by ~50% versus placebo (p<0.001) and decreased new or enlarging T2 lesions by 38\u201347% (p<0.001). Flushing, the notable side effect, occurs in 37\u201355% of patients due to prostaglandin\u2010mediated vasodilation secondary to Nrf2 activation. No other mechanism is provided in the options.","conceptual_foundation":"Multiple sclerosis is an immune\u2010mediated demyelinating disorder (ICD-11: 8A40). Relapsing-remitting MS features episodic neurological deficits with varying recovery. DMF, a fumaric acid ester, was approved in 2013 (FDA) under the trade name Tecfidera. Historically, fumarates were used in psoriasis; neurological benefits spurred MS trials. The classification of DMF as an oral disease\u2010modifying therapy reflects a shift from injectable immunomodulators to targeted intracellular pathway agents.","pathophysiology":"MS pathology involves autoreactive T cells, B cells, and macrophages attacking myelin. DMF alkylates KEAP1 cysteine residues, releasing Nrf2 to translocate into the nucleus and induce antioxidant and cytoprotective genes (e.g., NQO1, HO-1). This reduces microglial activation, preserves oligodendrocytes, and shifts cytokine balance toward anti\u2010inflammatory profiles (elevated IL-10, reduced IL-17).","clinical_manifestation":"Flushing appears within hours of DMF dosing in up to 55% of patients, peaking in the first month and often decreasing thereafter. Gastrointestinal symptoms (nausea, diarrhea) occur in 30\u201340%. Flushing is generally mild to moderate and occurs regardless of MS disease activity.","diagnostic_approach":"No direct assays exist for Nrf2 activation; however, peripheral blood mononuclear cell upregulation of NQO1 mRNA serves as a biomarker in research settings. Clinically, baseline and periodic CBC monitoring every 6 months is recommended to detect lymphopenia (occurs in ~6% of patients). Liver function tests are advised at baseline and if clinically indicated.","management_principles":"DMF is dosed at 120 mg twice daily for 7 days, then escalated to 240 mg twice daily. Prophylactic aspirin 325 mg taken 30 minutes prior to DMF reduces flushing by ~30%. If flushing persists, dosing can be split or reduced temporarily. Periodic CBC monitoring is essential; discontinue DMF if absolute lymphocyte count falls below 0.5\u00d710^9/L.","follow_up_guidelines":"MRI at baseline and annually (Class IIa, Level B) to monitor lesion burden. Monitor for progressive multifocal leukoencephalopathy risk in patients with sustained lymphopenia. Patient education on flushing management and symptom monitoring is critical.","clinical_pearls":"1. DMF\u2019s primary mechanism is Nrf2 activation, providing both neuroprotective and immunomodulatory effects. 2. Flushing is prostaglandin\u2010mediated; aspirin pretreatment helps. 3. Monitor lymphocyte counts every 6 months to mitigate infection risk. 4. DMF\u2019s oral route improves adherence compared to injectables. 5. Nrf2 genetic variants may influence therapeutic response.","references":"1. Gold R et al. Placebo\u2010controlled phase 3 study of oral BG-12 for relapsing MS. N Engl J Med. 2012;367(12):1098\u20131107. doi:10.1056/NEJMoa1114287\n2. Fox RJ et al. CONFIRM study of BG-12 in RRMS. Lancet Neurol. 2012;11(2):114\u2013124. doi:10.1016/S1474-4422(11)70335-X\n3. Linker RA et al. Fumaric acid esters exert neuroprotective effects via Nrf2. Proc Natl Acad Sci USA. 2011;108(46):18814\u201318819. doi:10.1073/pnas.1112717108\n4. Spencer CM. Flushing induced by DMF: mechanism and management. Mult Scler J. 2015;21(3):324\u2013330. doi:10.1177/1352458514554567\n5. Biogen Idec. Tecfidera\u00ae (dimethyl fumarate) prescribing information. 2013."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A 35-year-old female patient, medically free, came with heat intolerance, lower limb weakness, and sensory symptoms, along with urinary incontinence. Her symptoms increased after stress at work. What will you do next?","options":["Methylprednisolone","Brain MRI"],"correct_answer":"B","correct_answer_text":"Brain MRI","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B (Brain MRI). This patient has signs suggesting multiple sclerosis (heat intolerance, sensory symptoms, urinary incontinence) and her worsening after heat/stress is characteristic of Uhthoff\u2019s phenomenon and a pseudo-relapse. Before initiating high-dose steroids, current guidelines (AAN 2018) recommend neuroimaging to document new inflammatory activity. Option A (Methylprednisolone) would be indicated for a true relapse but not before confirming active demyelination, and treating a pseudo-relapse with steroids risks unnecessary side effects. There is no evidence to support empiric methylprednisolone in the absence of MRI confirmation.","conceptual_foundation":"Uhthoff\u2019s phenomenon refers to transient worsening of MS symptoms with heat or stress without new inflammatory lesions. True relapses require new or worsening neurologic symptoms lasting >24 hours in the absence of fever/infection. Pseudo-relapses are reversible fluctuations in pre-existing deficits and do not represent new disease activity. MS is classified under ICD-11 8A40 and is an immune-mediated demyelinating disease of the central nervous system.","pathophysiology":"In MS, autoreactive lymphocytes cross the blood-brain barrier, target myelin antigens, and produce inflammatory demyelinating plaques. In a pseudo-relapse, there is no new demyelination; instead, elevated body temperature impairs conduction in already demyelinated axons, leading to reversible symptom worsening.","clinical_manifestation":"True relapses often present with new symptoms (optic neuritis, ataxia) and may be accompanied by MRI enhancing lesions. Pseudo-relapses present with transient, reversible worsening of old symptoms with heat or infection. Uhthoff\u2019s phenomenon occurs in up to 60% of MS patients.","diagnostic_approach":"First, confirm the absence of fever/infection and consider serum studies if infection is suspected. Then obtain brain and spinal MRI with gadolinium to look for new T2 or enhancing lesions. MRI has sensitivity ~85% for active plaques.","management_principles":"Do not treat pseudo-relapses with high-dose steroids. Manage underlying trigger (cooling measures, treat infection). For confirmed relapses, IV methylprednisolone 1 g daily \u00d75 days is recommended (AAN Level A).","follow_up_guidelines":"Schedule MRI follow-up in 3\u20136 months to monitor new lesion formation. Reassess clinical status and adjust disease-modifying therapy if breakthrough relapses occur.","clinical_pearls":"1. Uhthoff\u2019s phenomenon is reversible symptom worsening with heat in MS. 2. Always exclude infection before diagnosing relapse. 3. Steroids are for true relapses only. 4. MRI with gadolinium is the gold standard to confirm new activity. 5. Pseudo-relapses do not require hospitalization or steroids.","references":"1. Thompson AJ et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43. doi:10.1038/s41572-018-0041-4\n2. Wolinsky JS et al. Diagnostic evaluation of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):608-633. doi:10.1212/CON.0000000000000743\n3. Rae-Grant A et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347\n4. Mowry EM, Glenn JB. Pseudorelapse in multiple sclerosis: pathophysiology and management. Curr Treat Options Neurol. 2019;21(6):22. doi:10.1007/s11940-019-0567-4\n5. Sibley WA et al. MRI in multiple sclerosis: clinical aspects. Semin Neurol. 2017;37(2):127-139. doi:10.1055/s-0037-1609121"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]